A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2

NCT05911087 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

800

Enrollment

INDUSTRY

Sponsor class

Conditions

Immunogenicity
Safety

Interventions

BIOLOGICAL: Phase II:SWIM816;SARS-Cov-2;
BIOLOGICAL: Phase II:SW-BIC-213;SARS-Cov-2;
BIOLOGICAL: PhaseIII:SWIM816;SARS-Cov-2;
BIOLOGICAL: PhaseIII:Pfizer(Pfizer Bivalent vaccine);SARS-Cov-2；

Sponsor

Stemirna Therapeutics